Hair loss is such a common experience that many people go through, but it can seem like it hits us out of nowhere. There are ...

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia ...

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

André Chaker is not like the other kids at Ridgeline High School. With a college soccer scholarship in hand to Northwest ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Alopecia is the general medical term for hair loss, which can come in different forms and severities. Hair loss is a common ...

ALY-101 is designed for local and selective modulation of inflammation and targets JAK1, a key driver of alopecia areata, with a JAK1-targeting siRNA-lipid conjugate. For the initial indication ...

Ivarmacitinib at both 4 mg and 8 mg doses was found to be efficacious in treating alopecia areata in a phase 3 trial.